2,5,6,8-tetrahydro-3H-imidazo[2,1-c][1,4]oxazine | 60928-27-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 英文名称: 2,5,6,8-tetrahydro-3H-imidazo[2,1-c][1,4]oxazine
• 英文别名: 2,3,5,6-tetrahydro-8H-imidazo[2,1-c] [1,4]-oxazine；2,5,6,8-tetrahydro-3H-imidazo[2,1-c][1,4]oxazine；3,5,6,8-tetrahydro-2H-imidazo[2,1-c][1,4]oxazine
• CAS: 60928-27-0
• 化学式: C₆H₁₀N₂O
• 分子量: 126.158
• InChiKey: KGLZPJGSKNCEOT-UHFFFAOYSA-N

物化性质

• 沸点：
  267.2±33.0 °C(Predicted)
• 密度：
  1.34±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.9
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  24.8
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  3-吗啉酮 、 2-溴乙胺氢溴酸盐 生成 2,5,6,8-tetrahydro-3H-imidazo[2,1-c][1,4]oxazine
  参考文献：
  名称：

  Cyclic amidine inhibitors of indolamine N-methyltransferase

  摘要：

  Syntheses of a large number of mono- and bicyclic, as well as a few tricyclic, amidine derivatives related to 2,3,4,6,7,8,-hexahydropyrrolo[1,2-a]pyrimidine (DBN) are reported. In vitro potencies for inhibition of the enzyme indolamine N-methyltransferase (INMT) from rabbit and human lung are presented. Four bicyclic amidine derivatives and 11 monocyclic derivatives were found to be equal or superior to DBN in in vitro potencies. With the bicyclic amidines, increasing ring size or introduction of substituents reduced activity. Among the monocyclic analogues, the most potent representatives were five- or six-membered systems with an exocyclic imino group, combined with methyl of ethyl substituents on the endocyclic nitrogen. Introduction of additonal substituents decreased inhibitory potency. 2,3,5,6-Tetrahydro-8H-imidazo[2,1-c][1,4]thiazine and 3-methyl-2-iminothiazolidine have been shown to cause inhibition of lung INMT when administered orally to rabbits.

  DOI：

  10.1021/jm00189a004

文献信息

• CIS-MORPHOLINONE AND OTHER COMPOUNDS AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER
  申请人：AMGEN INC.

  公开号：US20160002185A1

  公开（公告）日：2016-01-07

  The present invention provides MDM2 inhibitor compounds of Formula (I), or the pharmaceutically acceptable salts thereof, wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.

  本发明提供了公式（I）的MDM2抑制剂化合物或其药学上可接受的盐，其中变量如上所定义，这些化合物可用作治疗剂，特别是用于治疗癌症。本发明还涉及含有MDM2抑制剂的药物组合物。
• CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer
  申请人：AMGEN INC.

  公开号：US11407721B2

  公开（公告）日：2022-08-09

  The present invention provides MDM2 inhibitor compounds of Formula I, or the pharmaceutically acceptable salts thereof, wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.

  本发明提供了式 I 的 MDM2 抑制剂化合物或其药学上可接受的盐类、 其中变量定义如上，这些化合物可用作治疗剂，特别是用于治疗癌症。本发明还涉及含有 MDM2 抑制剂的药物组合物。
• US3973017A
  申请人：——

  公开号：US3973017A

  公开（公告）日：1976-08-03